Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.

ABSTRACT:

Background

Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial growth factor A (VEGF-A) production that induces a specific vascular phenotype. We previously reported that this phenotype may allow shedding of multicellular tumor fragments into the circulation, possibly contributing to the development of metastasis. Disruption of this phenotype through inhibition of VEGF signaling may therefore result in reduced shedding of tumor fragments and improved prognosis. To test this hypothesis, we investigated the effect of neoadjuvant sorafenib treatment on tumor cluster shedding.

Patients and methods

Patients with renal cancer (n = 10, of which 8 have ccRCC) received sorafenib for 4 weeks before tumor nephrectomy. The resection specime

SUBMITTER: Kats-Ugurlu G 

PROVIDER: S-EPMC4094826 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature